NYSE: ELV Elevance Health, Inc. 8-K

Elevance Health reaffirms 2026 guidance: adjusted EPS ≥$26.75, benefit expense ratio 90.2%±50bps

Filed June 10, 2026 · Period ending June 10, 2026 · ~1 min read

Key Changes

high

Reaffirmed full-year 2026 adjusted EPS guidance of at least $26.75 per share (reported EPS at least $19.85 including ~$6.90 of net unfavorable items)

Item 7.01 — Regulation FD Disclosure verify on EDGAR →
high

Reaffirmed benefit expense ratio guidance of 90.2% ±50 bps (range: 89.7%–90.7%), a key medical cost profitability metric

Item 7.01 — Regulation FD Disclosure verify on EDGAR →

Summary

Elevance Health reaffirmed its full-year 2026 financial guidance ahead of investor meetings, maintaining expectations for adjusted earnings of at least $26.75 per diluted share and a benefit expense ratio of 90.2% plus or minus 50 basis points. The reported earnings guidance of at least $19.85 per share includes approximately $6.90 of net unfavorable items already disclosed in the first quarter. For retail investors, this reaffirmation signals management's confidence in the company's ability to meet its previously stated targets despite any market volatility or operational challenges that may have emerged since the original guidance.

The benefit expense ratio—which measures medical costs as a percentage of premium revenue—is a critical profitability metric for health insurers, and the narrow 50-basis-point range (89.7%–90.7%) suggests management sees limited variability in medical cost trends for the remainder of the year. This is a routine disclosure with no material change to prior expectations.